Analysis of Chromatin Accessibility in Peripheral Blood Mononuclear Cells from Patients with Early-stage Breast Cancer

Overview

Journal Front Pharmacol

Date 2024 Oct 8

PMID 39376611

Authors

Longjie Xia

Jiamin Lu

Yixuan Qin

Runchun Huang

Fanbiao Kong

Yu Deng

Affiliations

Soon will be listed here.

Abstract

This study was aimed at exploring a specific open region of chromatin in the peripheral blood mononuclear cells (PBMCs) of patients with breast cancer and evaluating its feasibility as a biomarker for diagnosing and predicting breast cancer prognosis. We obtained PBMCs from breast cancer patients and healthy people for the assay for transposase-accessible chromatin (ATAC) sequencing (n = 3) and obtained the GSE27562 chip sequencing data for secondary analyses. Through bioinformatics analysis, we mined the pattern changes for chromatin accessibility in the PBMCs of breast cancer patients. A total of 1,906 differentially accessible regions (DARs) and 1,632 differentially expressed genes (DEGs) were identified via ATAC sequencing. The upregulated DEGs in the disease group were mainly distributed in the cells, organelles, and cell-intima-related structures and were mainly responsible for biological functions such as cell nitrogen complex metabolism, macromolecular metabolism, and cell communication, in addition to functions such as nucleic acid binding, enzyme binding, hydrolase reaction, and transferase activity. Combined with microarray data analysis, the following set of nine DEGs showed intersection between the ATAC and microarray data: JUN, MSL2, CDC42, TRIB1, SERTAD3, RAB14, RHOB, RAB40B, and PRKDC. HOMER predicted and identified five transcription factors that could potentially bind to these peak sites, namely NFY, Sp 2, GFY, NRF, and ELK 1. Chromatin accessibility analysis of the PBMCs from patients with early-stage breast cancer underscores its potential as a significant avenue for biomarker discovery in breast cancer diagnostics and treatment. By screening the transcription factors and DEGs related to breast cancer, this study provides a comprehensive theoretical foundation that is expected to guide future clinical applications and therapeutic developments.

References

Wang X, Yan J, Shen B, Wei G . Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells. Front Cell Dev Biol. 2021; 9:708066. PMC: 8363264. DOI: 10.3389/fcell.2021.708066. View

Yan L, Wang A, Lv Z, Yuan Y, Xu Q . Mitochondria-related core genes and TF-miRNA-hub mrDEGs network in breast cancer. Biosci Rep. 2021; 41(1). PMC: 7843495. DOI: 10.1042/BSR20203481. View

Buenrostro J, Giresi P, Zaba L, Chang H, Greenleaf W . Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013; 10(12):1213-8. PMC: 3959825. DOI: 10.1038/nmeth.2688. View

Li Y, Liu L, Lv Y, Zhang Y, Zhang L, Yu H . Silencing long non-coding RNA HNF1A-AS1 inhibits growth and resistance to TAM of breast cancer cells via the microRNA-363/SERTAD3 axis. J Drug Target. 2021; 29(7):742-753. DOI: 10.1080/1061186X.2021.1878362. View

Wieland A, Strissel P, Schorle H, Bakirci E, Janzen D, Beckmann M . Brain and Breast Cancer Cells with PTEN Loss of Function Reveal Enhanced Durotaxis and RHOB Dependent Amoeboid Migration Utilizing 3D Scaffolds and Aligned Microfiber Tracts. Cancers (Basel). 2021; 13(20). PMC: 8533830. DOI: 10.3390/cancers13205144. View

Jacob A, Jing J, Lee J, Schedin P, Gilbert S, Peden A . Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. J Cell Sci. 2013; 126(Pt 20):4647-58. PMC: 3795337. DOI: 10.1242/jcs.126573. View

Privat M, Cavard A, Zekri Y, Ponelle-Chachuat F, Molnar I, Sonnier N . A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors. Int J Med Sci. 2020; 17(17):2799-2808. PMC: 7645338. DOI: 10.7150/ijms.43101. View

Ahmad A, Zhang W, Wu M, Tan S, Zhu T . Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes. Genes Genomics. 2018; 40(3):243-251. DOI: 10.1007/s13258-017-0624-6. View

Lai Z, Moravcova S, Canitrot Y, Andrzejewski L, Walshe D, Rea S . Msl2 is a novel component of the vertebrate DNA damage response. PLoS One. 2013; 8(7):e68549. PMC: 3706407. DOI: 10.1371/journal.pone.0068549. View

10.

Ding S, Chen X, Shen K . Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun (Lond). 2020; 40(8):329-344. PMC: 7427308. DOI: 10.1002/cac2.12078. View

11.

Medale-Giamarchi C, Lajoie-Mazenc I, Malissein E, Meunier E, Couderc B, Berge Y . RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Res. 2013; 15(1):R6. PMC: 3672819. DOI: 10.1186/bcr3377. View

12.

Gross D, Garrard W . Nuclease hypersensitive sites in chromatin. Annu Rev Biochem. 1988; 57:159-97. DOI: 10.1146/annurev.bi.57.070188.001111. View

13.

Li X, An M, Gao Z . In Hepatocellular Carcinoma, miRNA-296-3p Targets MSL2 and Suppresses Cell Proliferation and Invasion. J Oncol. 2021; 2021:7430468. PMC: 8660223. DOI: 10.1155/2021/7430468. View

14.

Keller Valsecchi C, Basilicata M, Georgiev P, Gaub A, Seyfferth J, Kulkarni T . RNA nucleation by MSL2 induces selective X chromosome compartmentalization. Nature. 2020; 589(7840):137-142. DOI: 10.1038/s41586-020-2935-z. View

15.

Khan S, Shukla S, Farhan M, Sinha S, Lakra A, Penta D . Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis. Life Sci. 2020; 256:117976. DOI: 10.1016/j.lfs.2020.117976. View

16.

Cruz-Collazo A, Ruiz-Calderon J, Picon H, Borrero-Garcia L, Lopez I, Castillo-Pichardo L . Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer. Mol Cancer Ther. 2021; 20(12):2420-2432. PMC: 8643341. DOI: 10.1158/1535-7163.MCT-21-0348. View

17.

Zhang Y, Yang W, Wen G, Tang H, Wu C, Wu Y . High expression of PRKDC promotes breast cancer cell growth via p38 MAPK signaling and is associated with poor survival. Mol Genet Genomic Med. 2019; 7(11):e908. PMC: 6825841. DOI: 10.1002/mgg3.908. View

18.

Buenrostro J, Wu B, Chang H, Greenleaf W . ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. Curr Protoc Mol Biol. 2015; 109:21.29.1-21.29.9. PMC: 4374986. DOI: 10.1002/0471142727.mb2129s109. View

19.

Adey A, Morrison H, Asan , Xun X, Kitzman J, Turner E . Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition. Genome Biol. 2010; 11(12):R119. PMC: 3046479. DOI: 10.1186/gb-2010-11-12-r119. View

20.

Vogt P . Jun, the oncoprotein. Oncogene. 2001; 20(19):2365-77. DOI: 10.1038/sj.onc.1204443. View